Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy
Details
Serval ID
serval:BIB_D47EB9F3C085
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy
Journal
Antiviral Therapy
ISSN
1359-6535 (Print)
Publication state
Published
Issued date
2007
Volume
12
Number
2
Pages
261-5
Notes
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Multicenter Study
Research Support, Non-U.S. Gov't
Abstract
OBJECTIVES: To assess the prevalence of abnormal testosterone and gonadotropin values in HIV-infected men before and after 2 years of combination antiretroviral therapy (cART). DESIGN: Multicentre cohort of HIV-infected adults. METHODS: We identified 139 Caucasian antiretroviral-naive male patients who started zidovudine/ lamivudine-based cART that was virologically successful over a 2 year period. Ninety-seven were randomly chosen and plasma hormone determinations of free testosterone (fT) and luteinizing hormone (LH) at baseline and after 2 years of cART were evaluated. RESULTS: At baseline 68 patients (70%) had subnormal fT levels. In these, LH levels were low in 44%, normal in 47% and high in 9%. There was a trend for an association between lower CD4+ T-cell counts and hypogonadism. Most participants had normal FSH levels. No significant changes of fT, LH and FSH levels were observed after 2 years of cART. CONCLUSIONS: Low fT levels, mainly with normal or low LH levels and thus indicating secondary hypogonadism, are found in the majority of HIV-infected men and do not resolve during 2 years of successful cART.
Keywords
Adult
Anti-HIV Agents/*therapeutic use
CD4 Lymphocyte Count
Cohort Studies
Drug Therapy, Combination
Follicle Stimulating Hormone/blood
HIV Infections/complications/*drug therapy/immunology/virology
HIV-1/*genetics
Humans
Hypogonadism/blood/epidemiology/*virology
Lamivudine/therapeutic use
Luteinizing Hormone/blood
Male
Prevalence
RNA, Viral/*blood
Reverse Transcriptase Inhibitors/*therapeutic use
Switzerland/epidemiology
Testosterone/blood
Time Factors
Treatment Outcome
Viral Load
Zidovudine/therapeutic use
Pubmed
Web of science
Create date
24/01/2008 20:44
Last modification date
20/08/2019 15:54